WEE1 and amyotrophic lateral sclerosis: Several protein kinase inhibitors, such as a c-KIT receptor inhibitor (Masitinib), a ROCK inhibitor (Fasudil), a Src/c-Abl inhibitor (Bosutinib), an mTOR inhibitor (Rapamycin), a RIPK1 inhibitor (DNL747), sodium phenylbutyrate-taurursodiol (Paganoni et al., 2020), and others are currently in clinical trials for ALS patients, and many protein kinase inhibitors are undergoing pharmaceutical development (Palomo et al., 2021).